Keyword Index

B

  • Blood transfusion Screening of Occult Hepatitis B Virus Infection among Egyptian Blood Donors. [5.2, Issue 2, 2021, Pages 27-31]

C

  • Cirrhosis Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
  • Cirrhosis Macrophage Inflammatory Protein Type 1 Beta as a Novel Diagnostic Marker for Diagnosis of Spontaneous Bacterial Peritonitis [5.2, Issue 2, 2021, Pages 16-20]
  • Coagulopathy Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
  • Coronavirus disease Misuse of anticoagulants in COVID-19 patient: A case of gastrointestinal bleeding [5.2, Issue 2, 2021, Pages 1-2]
  • COVID-19 Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]

D

  • Daclatasvir Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]
  • D-Dimer Coagulopathy in COVID-19 from Pathogenesis until Treatment: A systemic Review [5.2, Issue 2, 2021, Pages 3-8]
  • Direct acting antiviral Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]
  • Direct acting antivirals Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]

H

  • Hemoglobin Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]
  • Hepatitis B virus Screening of Occult Hepatitis B Virus Infection among Egyptian Blood Donors. [5.2, Issue 2, 2021, Pages 27-31]
  • Hepatocellular carcinoma Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]

L

  • Lipid profile Impact of Direct-Acting Antiviral Agents Treatment on Body Mass Index and Lipid Profile in Egyptian Chronic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 21-26]

R

  • Ribavirin Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]

S

  • Sofosbuvir Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin. [5.2, Issue 2, 2021, Pages 32-39]
  • Spontaneous Bacterial Peritonitis Macrophage Inflammatory Protein Type 1 Beta as a Novel Diagnostic Marker for Diagnosis of Spontaneous Bacterial Peritonitis [5.2, Issue 2, 2021, Pages 16-20]

T

  • Thioredoxin Serum Thioredoxin as a Diagnostic Marker for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients [5.2, Issue 2, 2021, Pages 9-15]